EPIDERMOLYSIS BULLOSA
Clinical trials for EPIDERMOLYSIS BULLOSA explained in plain language.
Never miss a new study
Get alerted when new EPIDERMOLYSIS BULLOSA trials appear
Sign up with your email to follow new studies for EPIDERMOLYSIS BULLOSA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy aims to heal wounds in rare skin disease
Disease control Recruiting nowThis study tests whether adding IV IgG treatment to standard VYJUVEK therapy can help wounds heal faster and reduce blistering in people with recessive dystrophic epidermolysis bullosa (RDEB), a rare genetic skin condition. Eight participants will receive IV IgG alongside their u…
Matched conditions: EPIDERMOLYSIS BULLOSA
Phase: PHASE1, PHASE2 • Sponsor: M. Peter Marinkovich • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New gel could help heal wounds in rare skin disease
Disease control Recruiting nowThis study tests a gel called Oleogel-S10 on skin wounds in people with inherited epidermolysis bullosa (EB), a condition that causes fragile, blistering skin. The trial includes 6 Japanese children and adults with junctional or dystrophic EB. Participants apply the gel to wounds…
Matched conditions: EPIDERMOLYSIS BULLOSA
Phase: PHASE3 • Sponsor: Chiesi Farmaceutici S.p.A. • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New eye drop battle: which offers better dry eye relief?
Symptom relief Recruiting nowThis study compares two preservative-free eye drops, Artelac Complete MDO and VISMED MULTI, for treating moderate to severe dry eye disease. About 160 adults who have used tear substitutes for at least a month will use one of the two drops for 90 days. Researchers will measure ch…
Matched conditions: EPIDERMOLYSIS BULLOSA
Phase: NA • Sponsor: Dr. Gerhard Mann chem.-pharm. Fabrik GmbH • Aim: Symptom relief
Last updated Jun 27, 2026 12:34 UTC